X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SANOFI INDIA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SANOFI INDIA DIVIS LABORATORIES/
SANOFI INDIA
 
P/E (TTM) x 18.1 30.1 60.3% View Chart
P/BV x 3.9 5.3 73.9% View Chart
Dividend Yield % 1.6 1.7 92.8%  

Financials

 DIVIS LABORATORIES   SANOFI INDIA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
SANOFI INDIA
Dec-16
DIVIS LABORATORIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,4844,560 54.5%   
Low Rs9184,400 20.9%   
Sales per share (Unadj.) Rs142.31,028.5 13.8%  
Earnings per share (Unadj.) Rs41.9129.0 32.5%  
Cash flow per share (Unadj.) Rs46.3186.0 24.9%  
Dividends per share (Unadj.) Rs10.0068.00 14.7%  
Dividend yield (eoy) %0.61.5 38.7%  
Book value per share (Unadj.) Rs161.5753.6 21.4%  
Shares outstanding (eoy) m265.4723.03 1,152.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.04.4 274.5%   
Avg P/E ratio x40.634.7 116.9%  
P/CF ratio (eoy) x36.724.1 152.4%  
Price / Book Value ratio x10.55.9 177.1%  
Dividend payout %23.952.7 45.3%   
Avg Mkt Cap Rs m451,525103,174 437.6%   
No. of employees `0003.73.6 102.3%   
Total wages/salary Rs m3,6493,592 101.6%   
Avg. sales/employee Rs Th10,184.46,537.7 155.8%   
Avg. wages/employee Rs Th984.1991.4 99.3%   
Avg. net profit/employee Rs Th2,998.5819.8 365.8%   
INCOME DATA
Net Sales Rs m37,76423,686 159.4%  
Other income Rs m848708 119.8%   
Total revenues Rs m38,61224,394 158.3%   
Gross profit Rs m14,1385,281 267.7%  
Depreciation Rs m1,1821,313 90.0%   
Interest Rs m2315 154.7%   
Profit before tax Rs m13,7814,661 295.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,6621,691 157.4%   
Profit after tax Rs m11,1192,970 374.4%  
Gross profit margin %37.422.3 167.9%  
Effective tax rate %19.336.3 53.3%   
Net profit margin %29.412.5 234.8%  
BALANCE SHEET DATA
Current assets Rs m30,94715,673 197.5%   
Current liabilities Rs m5,1956,678 77.8%   
Net working cap to sales %68.238.0 179.6%  
Current ratio x6.02.3 253.8%  
Inventory Days Days11776 153.6%  
Debtors Days Days8522 381.6%  
Net fixed assets Rs m17,0278,098 210.3%   
Share capital Rs m531230 230.5%   
"Free" reserves Rs m42,34117,088 247.8%   
Net worth Rs m42,87717,356 247.0%   
Long term debt Rs m50-   
Total assets Rs m49,68425,400 195.6%  
Interest coverage x595.0311.7 190.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 81.5%   
Return on assets %22.411.8 190.8%  
Return on equity %25.917.1 151.5%  
Return on capital %32.226.9 119.5%  
Exports to sales %85.324.5 348.1%   
Imports to sales %22.928.0 81.9%   
Exports (fob) Rs m32,1985,801 555.0%   
Imports (cif) Rs m8,6546,627 130.6%   
Fx inflow Rs m32,2707,145 451.7%   
Fx outflow Rs m8,7756,846 128.2%   
Net fx Rs m23,496299 7,858.2%   
CASH FLOW
From Operations Rs m10,3793,226 321.7%  
From Investments Rs m-4,135-1,555 265.9%  
From Financial Activity Rs m-6,241-1,818 343.3%  
Net Cashflow Rs m3-147 -2.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 11.8 14.4 81.9%  
FIIs % 19.0 14.6 130.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.5 163.8%  
Shareholders   31,796 15,184 209.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; IT Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the IT sector and power sector witnessing maximum selling pressure.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 21, 2017 12:27 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS